Home Cart Sign in  
Chemical Structure| 2271358-65-5 Chemical Structure| 2271358-65-5

Structure of UAMC-3203 HCl
CAS No.: 2271358-65-5

Chemical Structure| 2271358-65-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

UAMC-3203 HCl is a potent and selective Ferroptosis inhibitor with an IC50 of 12 nM.

Synonyms: UAMC-3203 (hydrochloride); UAMC-3203 hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of UAMC-3203 HCl

CAS No. :2271358-65-5
Formula : C25H38ClN5O2S
M.W : 508.12
SMILES Code : O=S(C1=CC=C(NC2CCCCC2)C(NCC3=CC=CC=C3)=C1)(NCCN4CCNCC4)=O.[H]Cl
Synonyms :
UAMC-3203 (hydrochloride); UAMC-3203 hydrochloride
MDL No. :MFCD32062758
InChI Key :WBZHHIZXEXJBSM-UHFFFAOYSA-N
Pubchem ID :137701964

Safety of UAMC-3203 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 25 nM 24 hours Inhibit FZKA-induced lipid peroxidation Front Pharmacol. 2022 Apr 13;13:851680
H1299 25 nM 24 hours Inhibit FZKA-induced lipid peroxidation Front Pharmacol. 2022 Apr 13;13:851680
H1650 25 nM 24 hours Inhibit FZKA-induced lipid peroxidation Front Pharmacol. 2022 Apr 13;13:851680
PC9 25 nM 24 hours Inhibit FZKA-induced lipid peroxidation Front Pharmacol. 2022 Apr 13;13:851680
Human corneal epithelial (HCE) cells 10 nM, 1 µM, 10 µM, 50 µM 3 hours Assess cytotoxicity of UAMC-3203. Cell viability was reduced to 75% and 39.2% at 10 µM and 50 µM, respectively, whereas 10 nM and 1 µM caused no toxicity. Pharmaceutics. 2022 Dec 29;15(1):118
Bone marrow-derived macrophages (BMDMs) 1 µM 4 hours To evaluate the protective effect of UAMC-3203 on erythrophagocytosis-induced ferroptosis. Results showed that UAMC-3203 significantly reduced lipid peroxidation and cell death. Angiogenesis. 2023 Nov;26(4):505-522
Human corneal epithelial (HCE) cells 10 nM, 1 µM, 10 µM, 50 µM 72 hours Evaluate the effect of UAMC-3203 on cell migration. Results showed significantly higher HCE cell migration at 10 nM and 1 µM (p<0.001 and p=0.003 vs. negative control), while 10 µM and 50 µM showed no notable effects. Pharmaceutics. 2022 Dec 29;15(1):118

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Choline-deficient L-amino acid-defined high-fat diet (CDAHFD) and high-fat high-fructose diet (HFHFD) models Subcutaneous osmotic minipumps 12.35 mg/kg 4 weeks To evaluate the inhibitory effect of UAMC-3203 on ferroptosis in CDAHFD and HFHFD models. Results showed that UAMC-3203 reduced ALT and steatosis, but had little effect on hepatocyte ballooning, lobular inflammation, and fibrosis. Cell Death Differ. 2024 Sep;31(9):1113-1126
ApoE−/− Fbn1C1039G+/− mice Western-type diet (WD)-induced atherosclerosis model Subcutaneous osmotic minipumps 12.35 mg/kg/day Daily administration for 8 weeks To evaluate the effect of UAMC-3203 on atherosclerosis. Results showed that UAMC-3203 significantly reduced carotid plaque thickness, especially in plaques with confirmed IP angiogenesis or hemorrhage. Angiogenesis. 2023 Nov;26(4):505-522
Female C57BL/6 mice Mild spinal cord injury model Intraperitoneal injection 15 mg/kg Daily for either early treatment group (1-14 days) or delayed treatment group (28-42 days) To evaluate the effects of UAMC-3203 on locomotor recovery and secondary damage after mild spinal cord injury. Results showed that both early and delayed treatments improved locomotor recovery and reduced secondary damage. Acta Neuropathol. 2024 Jun 22;147(1):106
Wistar rats Spinal cord injury model Intraperitoneal injection 5 mg/kg 7 consecutive days UAMC-3203 inhibits ferroptosis, reduces spinal cord tissue damage and motor neuron loss, mitigates the inflammatory response post-spinal cord injury, and enhances the restoration of motor function in rats Sci Rep. 2024 Aug 30;14(1):20180

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.84mL

1.97mL

0.98mL

19.68mL

3.94mL

1.97mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories